These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 22966091)

  • 1. Does insulin glargine increase the risk of cancer compared with other basal insulins?: A French nationwide cohort study based on national administrative databases.
    Fagot JP; Blotière PO; Ricordeau P; Weill A; Alla F; Allemand H
    Diabetes Care; 2013 Feb; 36(2):294-301. PubMed ID: 22966091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database.
    Blin P; Lassalle R; Dureau-Pournin C; Ambrosino B; Bernard MA; Abouelfath A; Gin H; Le Jeunne C; Pariente A; Droz C; Moore N
    Diabetologia; 2012 Mar; 55(3):644-53. PubMed ID: 22222504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine.
    Strandberg AY; Hoti FJ; Strandberg TE; Christopher S; Haukka J; Korhonen P
    PLoS One; 2016; 11(3):e0151910. PubMed ID: 27031113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study.
    Neumann A; Weill A; Ricordeau P; Fagot JP; Alla F; Allemand H
    Diabetologia; 2012 Jul; 55(7):1953-62. PubMed ID: 22460763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of rosuvastatin versus simvastatin in primary prevention among new users: a cohort study in the French national health insurance database.
    Neumann A; Maura G; Weill A; Ricordeau P; Alla F; Allemand H
    Pharmacoepidemiol Drug Saf; 2014 Mar; 23(3):240-50. PubMed ID: 24292987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group.
    Colhoun HM;
    Diabetologia; 2009 Sep; 52(9):1755-65. PubMed ID: 19603149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study.
    Ruiter R; Visser LE; van Herk-Sukel MP; Coebergh JW; Haak HR; Geelhoed-Duijvestijn PH; Straus SM; Herings RM; Stricker BH
    Diabetologia; 2012 Jan; 55(1):51-62. PubMed ID: 21956710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment persistence after initiating basal insulin in type 2 diabetes patients: A primary care database analysis.
    Pscherer S; Chou E; Dippel FW; Rathmann W; Kostev K
    Prim Care Diabetes; 2015 Oct; 9(5):377-84. PubMed ID: 25701545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effects of insulin glargine on the risk of breast cancer.
    Suissa S; Azoulay L; Dell'Aniello S; Evans M; Vora J; Pollak M
    Diabetologia; 2011 Sep; 54(9):2254-62. PubMed ID: 21614572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulins NPH, glargine, and detemir, and risk of severe hypoglycemia among working-age adults.
    Strandberg AY; Khanfir H; Mäkimattila S; Saukkonen T; Strandberg TE; Hoti F
    Ann Med; 2017 Jun; 49(4):357-364. PubMed ID: 28042719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer risk associated with insulin glargine among adult type 2 diabetes patients--a nationwide cohort study.
    Chang CH; Toh S; Lin JW; Chen ST; Kuo CW; Chuang LM; Lai MS
    PLoS One; 2011; 6(6):e21368. PubMed ID: 21738645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lower incidence of macrovascular complications in patients on insulin glargine versus those on basal human insulins: a population-based cohort study in Italy.
    Cammarota S; Bruzzese D; Catapano AL; Citarella A; De Luca L; Manzoli L; Masulli M; Menditto E; Mezzetti A; Riegler S; Putignano D; Tragni E; Novellino E; Riccardi G
    Nutr Metab Cardiovasc Dis; 2014 Jan; 24(1):10-7. PubMed ID: 23806740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similar Breast Cancer Risk in Women Older Than 65 Years Initiating Glargine, Detemir, and NPH Insulins.
    Bradley MC; Chillarige Y; Lee H; Wu X; Parulekar S; Wernecke M; Bright P; Soukup M; MaCurdy TE; Kelman JA; Graham DJ
    Diabetes Care; 2020 Apr; 43(4):785-792. PubMed ID: 32075848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment persistence in the use of basal insulins in Poland and Germany
.
    Rathmann W; Czech M; Franek E; Kostev K
    Int J Clin Pharmacol Ther; 2017 Feb; 55(2):119-125. PubMed ID: 27879196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cohort study of insulin glargine and risk of breast, prostate, and colorectal cancer among patients with diabetes.
    Habel LA; Danforth KN; Quesenberry CP; Capra A; Van Den Eeden SK; Weiss NS; Ferrara A
    Diabetes Care; 2013 Dec; 36(12):3953-60. PubMed ID: 24170756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin glargine use and breast cancer risk: Associations with cumulative exposure.
    Peeters PJ; Bazelier MT; Leufkens HG; Auvinen A; van Staa TP; de Vries F; De Bruin ML
    Acta Oncol; 2016 Jul; 55(7):851-8. PubMed ID: 27150973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study.
    Hemkens LG; Grouven U; Bender R; Günster C; Gutschmidt S; Selke GW; Sawicki PT
    Diabetologia; 2009 Sep; 52(9):1732-44. PubMed ID: 19565214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Electronic medical record cancer incidence over six years comparing new users of glargine with new users of NPH insulin.
    Lim S; Stember KG; He W; Bianca PC; Yelibi C; Marquis A; Stürmer T; Buse JB; Meigs JB
    PLoS One; 2014; 9(10):e109433. PubMed ID: 25329887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of a national administrative database to guide public decisions: From the système national d'information interrégimes de l'Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France.
    Tuppin P; Rudant J; Constantinou P; Gastaldi-Ménager C; Rachas A; de Roquefeuil L; Maura G; Caillol H; Tajahmady A; Coste J; Gissot C; Weill A; Fagot-Campagna A
    Rev Epidemiol Sante Publique; 2017 Oct; 65 Suppl 4():S149-S167. PubMed ID: 28756037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin glargine use and short-term incidence of malignancies - a three-year population-based observation.
    Ljung R; Talbäck M; Haglund B; Jonasson JM; Gudbjörnsdòttir S; Steineck G
    Acta Oncol; 2011 Jun; 50(5):685-93. PubMed ID: 21506898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.